Is continued treatment with Entyvio (Vedolizumab) 300 mg IV every 6 weeks appropriate and necessary for a patient with Crohn’s Disease of the small intestines, who is in clinical and endoscopic remission on Entyvio, after failing Stelara (Ustekinumab) and Humira (Adalimumab)?
Last updated: December 1, 2025 • View editorial policy
Help us tailor your experience
Which best describes you? Your choice helps us use language that's most understandable for you.
Related Questions
Professional Medical Disclaimer
This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.
Have a follow-up question?
Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.